The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
Physician-diagnosed asthma requiring treatment with medium- to high-dose ICS-LABA for at least 12 months prior to screening.
Pre-BD FEV1 < 80% predicted according to central over read value at Visit 2.
Documented historical post-BD reversibility of FEV1 ≥ 12% and ≥ 200 mL in FEV1.
At least 2 documented asthma exacerbations (requiring treatment with systemic CS, hospitalization, or emergency department visit) within 12 months prior to screening but not within the past 4 weeks prior to screening
Maintenance use of asthma controllers other than ICS-LABA.
Have undergone bronchial thermoplasty.
Current smokers or participants with a smoking history of ≥ 10 pack-years and participants using vaping products, including electronic cigarettes.
Women who are pregnant (or who are considering pregnancy) or breastfeeding.
Parallel
povorcitinib
Drugpovorcitinib
placebo
Other interventionplacebo
ICS-LABA
DrugBackground Therapy
Absolute change in pre-bronchodilator forced expiratory volume in the first 1 second (pre-BD FEV1)
To assess the effect of povorcitinib on lung function (pre-BD FEV1) between baseline and week 24
Number of asthma exacerbations during the Placebo Controlled (PC) period
Defined as a worsening of asthma
Absolute change from baseline in pre-BD FEV1 at each visit
Percent change from baseline in pre-BD FEV1 at each visit
Absolute change from baseline in post-BD FEV1 at week 24
Click on the lead sponsor to view all of their trials.
